Project Grant F30CA291106
Award Date
12/1/24
Completion Date
5/31/27
Dollars Obligated
$140K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Stanford, CA 94305, USA
Similar Awards
This $1,108,391.72 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to define the most therapeutically relevant chimeric antigen receptor (CAR) T cell subsets for treating large B cell lymphoma (LBCL) and overcome immune suppression mechanisms that limit CAR T cell efficacy. The funded project will use a systems biology approach to analyze patient data and pinpoint optimal CAR T cell characteristics for...
This federal Project Grant award of $207,900 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the CFDA 93.286 "Discovery and Applied Research for Technological Innovations to Improve Human Health" program supports research at The Leland Stanford Junior University (Stanford University) to develop a three-cell synthetic immunotherapy system. The goal is to engineer T cells, natural killer (NK) cells, and macrophages to express chimeric antigen...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $170,376 to The Leland Stanford Junior University to develop a rapid, label-free, and cost-effective technique for quantifying chimeric antigen receptor (CAR) T cells in patient blood samples using surface enhanced Raman spectroscopy (SERS) and machine learning. The project aims to optimize SERS methods for analyzing immune cell spectra, develop machine learning...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to harness B cells after stem cell transplant to produce novel chimeric antigen receptor T-cells (CAR-Ts) for treating hematological malignancies. The $415,257 award to Duke University, a leading research institution, will fund research to clone antibody-producing B cells with tumor-binding potential after hematopoietic stem cell transplantation. The goal is to engineer less toxic and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $931,841 to The Leland Stanford Junior University to develop next-generation immunotherapies for pediatric cancers. The funding will support research to overcome the suppressive tumor microenvironment in pediatric solid tumors, optimize multi-specific CAR T cells, and explore in vivo gene delivery approaches to engineer immune populations without ex vivo manufacturing. This work aims to...
This Project Grant award of $661,884 from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) supports research by Dr. Theodore Roth at Stanford University to dissect the intrinsic variability in engineered T cell immunotherapies for cancer treatment. The key objectives are to: 1) develop scalable screening methodologies to assay approved and proposed cellular immunotherapy constructs across large patient cohorts, 2) investigate the intrinsic variability of patient T...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $1,390,720 to The Leland Stanford Junior University (Stanford University) to develop an optimized chimeric antigen receptor (CAR) T-cell therapy targeting cerebroglycan (GPC2) for the treatment of medulloblastoma, the most common malignant brain tumor in children. The key objectives are to: 1) Define the optimal approach to overexpress the transcription factor cJun in...
This $195,766 federal Project Grant, awarded on December 19, 2024 by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research at Yale University to develop a mechano-transduction platform for enhancing chimeric antigen receptor (CAR) T-cell therapies for cancer immunotherapy. The key goals are to: 1) measure forces along immune receptors like the T-cell receptor and CAR using force sensors, and 2) engineer force transduction modules that can induce expression of...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) program, provides $176,040 to The General Hospital Corporation (Massachusetts General Hospital) from July 1, 2025 to June 30, 2027. The project aims to develop new strategies to engineer CAR-T cell therapies that can overcome the cancer cell glycocalyx barrier for improved immunotherapy, particularly for solid tumors like breast cancer and glioblastoma. Key objectives include...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $399,958 to Mabswitch Inc., a minority-owned small business, to assess the feasibility of regulating the activation, effector functions, and cytokine release of chimeric antigen receptor (CAR) T-cell therapies. The project aims to develop a "switchable affinity CAR" (SAEFCAR) that can be controlled by an exogenously administered ligand, potentially mitigating the toxicity...